To hear about similar clinical trials, please enter your email below
Trial Title:
The Utility of Cell-free DNA Methylation Markers for Hepatocellular Carcinoma
NCT ID:
NCT05573217
Condition:
Cell-free Methylation Markers
Conditions: Official terms:
Carcinoma, Hepatocellular
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Summary:
The subjects of this study were patients with liver cancer diagnosed by physicians
according to AASLD clinical criteria or pathological biopsy.
Those who plan to receive systemic drug treatment for liver cancer in National Taiwan
University Hospital include Nexavar, Lenvatinib, Avastin, Tecentriq, Strivarga,
Cabometyx, Cyramza, Nivolunab, Pembrolizumab, and Yervoy. Weak and uncooperative patients
were excluded from blood tests, which were performed with full informed consent for
relevant tumor markers (AFP ,PIVKA-II and methylation analysis). The data are then
counted and compared.
Criteria for eligibility:
Study pop:
Patients diagnosed with liver cancer by AASLD clinical criteria or pathological slides
Patients planning to receive systemic drug therapy for liver cancer at National Taiwan
University Hospital include Nexavar, Lenvatinib, Avastin, Tecentriq, Strivarga,
Cabometyx, Cyramza, Nivolunab, Pembrolizumab, and Yevoy.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
1. Patients diagnosed with liver cancer by AASLD clinical criteria or pathological
slides Patients planning to receive systemic drug therapy for liver cancer at
National Taiwan University Hospital include Nexavar, Lenvatinib, Avastin, Tecentriq,
Strivarga, Cabometyx, Cyramza, Nivolunab, Pembrolizumab, and Yevoy.
2. Over 20 years old.
3. In the case of informed consent, willing to sign the consent form of the subjects.
Exclusion Criteria:
1. Patients who are weak and unable to cooperate with blood test.
2. Kidney dysfunction, serum creatinine greater than 1.5 x UNL (normal value) and no
hemodialysis treatment, who are judged to be unwell for computed tomography or MRI
contrast agent injection.
Gender:
All
Minimum age:
20 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
National Taiwan University Hospital
Address:
City:
Taipei, Taiwan
Country:
Taiwan
Status:
Recruiting
Contact:
Last name:
Kai-Wen Huang, MD, PhD
Email:
fangyu0429@gmail.com
Start date:
July 1, 2021
Completion date:
June 30, 2023
Lead sponsor:
Agency:
National Taiwan University Hospital
Agency class:
Other
Source:
National Taiwan University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05573217
